Boehringer picks up bacterial cancer therapy specialist T3 Pharma

2023-11-22

免疫疗法临床1期并购

Boehringer Ingelheim on Wednesday said that it purchased privately-held T3 Pharmaceuticals for up to CHF 450 million ($508 million). "The acquisition…will significantly expand our immuno-oncology pipeline portfolio and is synergistic with many of our existing R&D programmes," said Michel Pairet, member of Boehringer Ingelheim's board responsible for the innovation unit.

T3 Pharma has developed a therapy platform that uses live engineered Yersinia enterocolitica bacteria to deliver bioactive proteins to cancerous cells and tumour micro-environments, while at the same time sparing healthy tissues. The bacteria can be loaded with multiple immune-modulatory proteins, allowing for the design of immuno-oncology combination therapies in one single agent, according to the German drugmaker.

Previous lead investor

T3 Pharma, which launched in 2015, closed a CHF 25 million ($28 million) financing in 2020, with Boehringer Ingelheim's Venture Fund co-leading the investment round. The company used the funds to advance its lead candidate, T3P-Y058-739, which was developed using its bacterial delivery platform and is currently in Phase I testing. According to T3 Pharma's website, the technology is built on the discovery that the bacterial type III secretion system can be repurposed to deliver chosen proteins into eukaryotic cells. Its pipeline also includes the preclinical assets T3P-Y098, T3P-1017 and T3P-1127.

"Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15% to 20% of cancer patients," said Boehringer Ingelheim. The company is looking to boost that rate via complementary immuno-oncology platforms such as T-cell engagers, oncolytic viruses and cancer vaccines, "which have the potential to turn cold tumours into hot ones, extending the benefits of immunotherapy to more patients," it added.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构